Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)2.01
  • Today's Change-0.06 / -2.90%
  • Shares traded5.76m
  • 1 Year change-19.92%
  • Beta0.9671
Data delayed at least 20 minutes, as of Mar 03 2026 05:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

  • Revenue in AUD (TTM)24.21m
  • Net income in AUD-143.78m
  • Incorporated2004
  • Employees81.00
  • Location
    Mesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
  • Phone+61 39639-6036
  • Fax+61 39639-6030
  • Websitehttps://www.mesoblast.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rubicon Research Ltd246.60m31.82m1.97bn1.14k59.18--51.977.9713.0713.07102.06--------14,424,080.00--------68.82--12.90----12.92----50.40--47.63------
Suzhou Ribo Life Science Co Ltd36.91m-45.23m1.97bn404.00------53.33-1.56-1.561.27-0.4122----------------90.90---131.95--0.9173-14.930.8949--324,052.30--36.93------
Pell Bio Med Technology Co Ltd1.34m-16.73m2.00bn----42.72--1,490.69-6.31-6.310.506816.150.01856.365.95---23.99---31.28---31.12---1,297.25--3.47--0.1652--8.86--2.34------
Nanjing Leads Biolabs Co Ltd0.00-58.85m2.12bn192.00--93.71-----2.02-2.020.000.6344------------------------1.01--0.7407---100.00--16.85------
Onesource Specialty Pharma Ltd219.00m3.21m2.32bn1.41k720.15--50.6110.581.821.76129.84--------10,051,880.00--------70.99--1.46----0.8886----740.43--95.27------
HitGen Inc102.15m23.38m2.32bn483.00100.057.70--22.710.28240.28241.243.670.27266.374.691,032,114.006.183.066.873.3655.2353.5522.6714.485.126.590.167434.3214.9910.0826.13-15.653.16--
InventisBio Co Ltd36.99m-23.83m2.48bn185.00--7.26--66.99-0.2012-0.20120.31222.880.0988--1.03975,824.70-6.36-32.89-6.76-35.2299.41---64.41-682.73----0.0127---9.0225.0015.41---3.97--
Syngene International Ltd574.02m54.33m2.56bn6.53k47.25--20.894.458.728.7292.16--------5,694,474.00--8.14--10.4475.2671.299.4615.03--5.73----4.4112.60-2.713.783.67--
Mesoblast Ltd91.92m-132.67m2.67bn81.00--3.30--29.06-0.1035-0.10350.07170.6270.09111.202.951,134,840.00-13.15-13.19-15.28-14.6857.98-132.14-144.33-957.401.41-4.740.1904--191.39-11.76-16.13---20.16--
Keymed Biosciences Inc178.72m-52.73m2.69bn1.47k--4.11--15.04-1.12-1.123.7812.200.20680.338215.10790,836.80-6.10-40.63-7.27-44.6095.19---29.48-593.203.74--0.2145--20.91---43.38--28.05--
Mabwell Shanghai Bioscience Co Ltd127.97m-194.15m2.74bn1.36k--17.60--21.45-2.37-2.371.561.900.13840.345814.57441,048.00-21.06-29.90-36.19-36.1888.7285.56-152.14-1,188.680.8093-10.820.7353--56.2846.680.9031--12.25--
Ascentage Pharma Group International80.04m-237.53m3.02bn605.00--20.68--37.72-4.05-4.051.362.180.12703.700.9505785,790.80-37.68-30.84-60.56-41.9490.8794.02-296.81-252.931.53--0.7174--341.77132.2556.20---21.49--
Telix Pharmaceuticals Ltd1.13bn-10.02m3.31bn1.12k--5.66163.542.93-0.0296-0.02963.341.720.763913.907.441,008,962.00-0.6772-4.82-0.8545-6.4147.5155.04-0.8864-5.751.273.640.5293--55.61195.18-121.15--202.38--
Data as of Mar 03 2026. Currency figures normalised to Mesoblast Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

15.65%Per cent of shares held by top holders
HolderShares% Held
State Street Global Advisors, Australia, Ltd.as of 08 Dec 202544.97m3.49%
M&G Investment Management Ltd.as of 31 Oct 202540.86m3.17%
The Vanguard Group, Inc.as of 04 Feb 202634.87m2.70%
Vanguard Investments Australia Ltd.as of 31 Jan 202619.14m1.48%
Thorney Investment Group Australia Pty Ltd.as of 30 Sep 202514.12m1.09%
Norges Bank Investment Managementas of 30 Jun 202512.25m0.95%
BlackRock Fund Advisorsas of 06 Feb 202612.07m0.94%
Dimensional Fund Advisors LPas of 05 Feb 20269.09m0.71%
BetaShares Capital Ltd.as of 30 Jan 20267.33m0.57%
DFA Australia Ltd.as of 31 Jan 20267.20m0.56%
More ▼
Data from 31 Dec 2025 - 27 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.